ERBB2 and cancer: In the testing cohort, models based on combined intratumoral and peritumoral PA radiomics features yielded an AUC of 0.846 for distinguishing HER2-zero from HER2-low/HER2-positive cancers, 0.801 for distinguishing HER2-low from HER2-positive cancers, and 0.767 for differentiating HER2-zero from HER2-low cancers.